Coya Therapeutics (COYA) News Today $7.04 -0.19 (-2.63%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 6.3% in OctoberCoya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totalling 186,100 shares, an increase of 6.3% from the September 30th total of 175,000 shares. Currently, 1.3% of the company's shares are sold short. Based on an average daily volume of 50,700 shares, the days-to-cover ratio is currently 3.7 days.November 1 at 3:13 PM | marketbeat.comCoya Therapeutics Announces Leadership Change and New CEONovember 1 at 1:32 PM | markets.businessinsider.comCoya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive OfficerNovember 1 at 1:32 PM | finance.yahoo.comCoya Therapeutics Approves Employment Agreements for Outgoing and Incoming CEOsNovember 1 at 2:05 AM | americanbankingnews.comCoya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial ResultsOctober 31 at 4:02 AM | finance.yahoo.comPromising Phase II Trial Results Support Buy Rating for Coya Therapeutics’ Alzheimer’s TreatmentOctober 31 at 4:02 AM | markets.businessinsider.comCoya Therapeutics' (COYA) Buy Rating Reaffirmed at Chardan CapitalChardan Capital reiterated a "buy" rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Wednesday.October 30 at 9:32 AM | marketbeat.comCoya Therapeutics says Phase 2 LD-1L-2 study met primary, secondary endpointsOctober 30 at 1:27 AM | markets.businessinsider.comCoya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trialOctober 29, 2024 | reuters.comCoya Therapeutics Announces Closing of $10.0 Million Private PlacementOctober 23, 2024 | stockhouse.comCoya Therapeutics (NASDAQ: COYA) Announces Private Placement OfferingOctober 23, 2024 | americanbankingnews.comCoya Therapeutics Announces $10M Private Placement to Advance PipelineOctober 22, 2024 | markets.businessinsider.comCoya Therapeutics to sell 1.379M shares at $7.25 in private placementOctober 22, 2024 | markets.businessinsider.comCoya Therapeutics Announces $10.0 Million Private PlacementOctober 22, 2024 | finance.yahoo.comCoya Therapeutics Shares Rise 9% After $10 Million Private PlacementOctober 22, 2024 | marketwatch.comExosomes Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and BarriersOctober 15, 2024 | theglobeandmail.comCoya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100October 8, 2024 | finance.yahoo.comCoya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines ConferenceSeptember 24, 2024 | finance.yahoo.comResearch Analysts Issue Forecasts for Coya Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:COYA)Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Equities researchers at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for Coya Therapeutics in a note issued to investors on Monday, September 16th. HC Wainwright analyst R. Selvaraju forecasts that the company will posSeptember 19, 2024 | marketbeat.comThis Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For MondaySeptember 17, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Coya Therapeutics (COYA) with Buy RecommendationSeptember 16, 2024 | nasdaq.comCoya Reports Anti-inflammatory Effect Of COYA 302 In Inflammatory Mouse Model Of Parkinson'sSeptember 16, 2024 | markets.businessinsider.comCoya Therapeutics (NASDAQ:COYA) Stock Quotes, Forecast and News SummarySeptember 16, 2024 | benzinga.comCoya Therapeutics (NASDAQ:COYA) Now Covered by HC WainwrightHC Wainwright started coverage on Coya Therapeutics in a report on Monday. They issued a "buy" rating and a $18.00 target price on the stock.September 16, 2024 | marketbeat.comCoya Therapeutics, Inc. (NASDAQ:COYA) Short Interest UpdateCoya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 15th, there was short interest totalling 160,700 shares, a decrease of 9.1% from the July 31st total of 176,700 shares. Based on an average daily trading volume, of 55,900 shares, the days-to-cover ratio is currently 2.9 days. Currently, 1.1% of the company's shares are sold short.September 3, 2024 | marketbeat.comCoya Therapeutics to Present at Upcoming Healthcare ConferencesSeptember 3, 2024 | finance.yahoo.comHere's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn SituationSeptember 3, 2024 | finance.yahoo.comCoya Therapeutics Names Arun Swaminathan Chief ExecutiveAugust 20, 2024 | marketwatch.comCoya Therapeutics Promotes Arun Swaminathan To CEOAugust 20, 2024 | markets.businessinsider.comEquities Analysts Issue Forecasts for Coya Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:COYA)Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Investment analysts at Chardan Capital raised their FY2024 earnings per share estimates for Coya Therapeutics in a report issued on Tuesday, August 13th. Chardan Capital analyst K. Nakae now anticipates that the company will post earnings of (August 16, 2024 | marketbeat.comCoya Therapeutics, Inc. (NASDAQ:COYA) Shares Acquired by Vanguard Group Inc.Vanguard Group Inc. lifted its stake in shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) by 772.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 847,490 shares of the company's stock aftAugust 16, 2024 | marketbeat.comChardan Capital Weighs in on Coya Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:COYA)Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Stock analysts at Chardan Capital issued their FY2025 earnings per share estimates for Coya Therapeutics in a report released on Tuesday, August 13th. Chardan Capital analyst K. Nakae forecasts that the company will post earnings of ($1.26) peAugust 15, 2024 | marketbeat.comCOYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024August 12, 2024 | markets.businessinsider.comCoya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial ResultsAugust 12, 2024 | finance.yahoo.comCoya Therapeutics (NASDAQ:COYA) Stock Price Down 2.9%Coya Therapeutics (NASDAQ:COYA) Trading Down 2.9%August 8, 2024 | marketbeat.comCoya reports Alzheimer's trial to present at CTAD24August 4, 2024 | investing.comCoya Therapeutics Blunders on Test ResultsAugust 2, 2024 | msn.comCoya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in MadridAugust 2, 2024 | businesswire.comShort Interest in Coya Therapeutics, Inc. (NASDAQ:COYA) Rises By 6.1%Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 187,800 shares, a growth of 6.1% from the June 15th total of 177,000 shares. Based on an average daily volume of 51,100 shares, the days-to-cover ratio is currently 3.7 days. Approximately 1.4% of the shares of the company are short sold.July 17, 2024 | marketbeat.comCoya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the ClinicJune 20, 2024 | businesswire.comCoya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Analysts at Rodman & RenshawRodman & Renshaw began coverage on shares of Coya Therapeutics in a research report on Thursday. They issued a "buy" rating and a $18.00 price objective for the company.June 13, 2024 | marketbeat.comCoya Therapeutics, Inc. (NASDAQ:COYA) Shares Acquired by Greenlight Capital Inc.Greenlight Capital Inc. lifted its position in Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) by 172.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,274,026 shares of the company's stock after purcJune 13, 2024 | marketbeat.comCoya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in NeurologyJune 3, 2024 | businesswire.comCoya Therapeutics Announces Inclusion in the MSCI USA Micro Cap IndexMay 28, 2024 | businesswire.comAIGH Capital Management LLC Buys 496,183 Shares of Coya Therapeutics, Inc. (NASDAQ:COYA)AIGH Capital Management LLC boosted its position in Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) by 92.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,031,977 shares of the company's stock after purchasing an additionalMay 27, 2024 | marketbeat.com7 Biotech Stocks to Put on Your Breakthrough RadarMay 27, 2024 | investorplace.comEXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare DiseasesMay 27, 2024 | finance.yahoo.comCoya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s DiseaseMay 22, 2024 | finance.yahoo.comCoya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's DiseaseMay 22, 2024 | businesswire.comCoya Therapeutics: ADDF To Support Clinical Development Of COYA 302 Through Equity InvestmentMay 20, 2024 | markets.businessinsider.com Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here COYA Media Mentions By Week COYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COYA News Sentiment▼0.260.41▲Average Medical News Sentiment COYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COYA Articles This Week▼102▲COYA Articles Average Week Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Contineum Therapeutics News Today GH Research News Today Cartesian Therapeutics News Today 4D Molecular Therapeutics News Today Esperion Therapeutics News Today C4 Therapeutics News Today Amylyx Pharmaceuticals News Today Voyager Therapeutics News Today MeiraGTx News Today Alpha Teknova News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COYA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
